APR 02, 2018 6:37 PM PDT

Treating Rare Pediatric Cancers

WRITTEN BY: Nouran Amin

Research published in The Lancet Oncology explains how the drug Larotrectinib can treat cancer cells that have a specific fusion of two genes. Larotrectinib received FDA designation and can treat any cancer type with a fusion gene. "In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion. When this occurs, it leads to the TRK gene being turned on when it's not supposed to be and that causes the cells to grow uncontrollably. What's unique about the drug is it is very selective; it only blocks TRK receptors," said lead investigator Dr. Ted Laetsch, a Professor of Pediatrics at Harold C. Simmons Comprehensive Cancer Center.

Larotrectinib is part of a group molecules designated as ‘kinase inhibitors’ which work to cut back on the enzyme actions of cellular mechanisms. In this case, Larotrectinib targets TRK fusions which are present in many types of cancers, including lung, colon, thyroid, and breast cancer, as well as certain pediatric tumors. Some TRK fusions occur in only a small percentage of common adult cancers however the rest are more commonly seen in rare pediatric cancers including infantile fibrosarcoma, cellular congenital mesoblastic nephroma, and papillary thyroid cancer. "Every patient with a TRK fusion-positive solid tumor treated on this study had their tumor shrink. The nearly universal response rate seen with larotrectinib is unprecedented," explains Dr. Laetsch.

One child treated with Larotrectinib was 13-year-old aspiring fashion designer Briana Ayala of El Paso. Briana had a rare tumor located in her abdomen and wrapped around her aorta, which made it risky for surgical operation. So, Briana and her family were there encouraged to visit Children’s Health in Dallas, TX where she underwent a specialized operation that removed only portions of her aorta and most of the tumor. Unfortunately, this did not treat Briana’s cancer as it began to return. With no treatments available, Dr. Laetsch sent Briana’s tumor for genetic testing where it was analyzed to have a TRK fusion making it possible to be treated by Larotrectinib

After Briana’s enrollment in phase 1 clinical trial of the new drug, results have shown that swelling in her abdomen has been diminished along with a shrunken tumor. "These are the kind of amazing responses we've seen with larotrectinib," said Dr. Laetsch, "and this is why I'm so excited about it."

What’s particularly unique about larotrectinib is it doesn’t lead to severe side effects like most other cancer therapeutics and for many patients the response was long-lasting. "For some of the targeted drugs in the past, many patients responded initially, but then resistance developed quickly. To date, the response to this drug seems to be durable in most patients," said Dr. Laetsch.

Sources: The Lancet Oncology, Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 18, 2019
Drug Discovery & Development
NOV 18, 2019
FDA Approves New Drug for Sickle Cell Disease
Sickle cell disease affects approximately 100,000 Americans. Currently, the only available cure for the disease is a costly bone marrow transplant, putting...
NOV 19, 2019
Drug Discovery & Development
NOV 19, 2019
Antibiotics from the Sea?
Many of the clinically relevant antibiotics are sourced from natural substances, produced by bacteria. But because of the growing threat of antibiotic resi...
DEC 09, 2019
Drug Discovery & Development
DEC 09, 2019
Could the diabetic drug 'metformin' extend a healthy lifespan?
The most commonly prescribed diabetic medication for the Type 2 condition is ‘Metformin’—a drug with a mysterious mechanism of action but...
DEC 17, 2019
Cell & Molecular Biology
DEC 17, 2019
A New Tool for Assessing the Impact of Drugs on Single Cells
When scientists assess the impact of a treatment like a drug on cells, they usually generally rely on large populations of cells to find general trends....
JAN 09, 2020
Drug Discovery & Development
JAN 09, 2020
Can Cancer Drugs Treat Lung Damage?
Can therapeutics used in the treatment of cancer be a breakthrough for pulmonary disease? Specifically, chronic obstructive pulmonary disease (COPD)? &ldqu...
FEB 11, 2020
Cannabis Sciences
FEB 11, 2020
Traffic Light System Best Way to Label Cannabis Edibles
Cannabis products have become increasingly popular. Yet, as they are still relatively new to the market, research has found that most consumers don’t...
Loading Comments...